Experience of Nusinersen in children with proximal spinal muscular atrophy 5q in Moscow region
Background. Proximal spinal muscular atrophy 5q (5q-SMA) is a severe autosomal recessive neuromuscular disorder characterized by progressive flaccid paralysis and muscular atrophy caused by degeneration of α-motor neurons in the anterior horns of the spinal cord resulted from mutations in the SMN1 g...
Saved in:
Main Author: | M. V. Panteleeva |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2022-12-01
|
Series: | Русский журнал детской неврологии |
Subjects: | |
Online Access: | https://rjdn.abvpress.ru/jour/article/view/404 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Experience with nusinersen as a pathogenetic therapy in adult patients with spinal muscular atrophy 5q in the Republic of Bashkortostan
by: S. V. Umutbaev, et al.
Published: (2023-03-01) -
Molecular markers of disease severity and response to nusinersen therapy in 5q spinal muscular atrophy (literature review)
by: K. D. Popov, et al.
Published: (2023-10-01) -
The efficacy and safety of nusinersen within the expanded access program in Russia
by: S. B. Artemieva, et al.
Published: (2020-12-01) -
Diagnostic criteria for spinal muscular atrophy 5q
by: I. V. Sharkova, et al.
Published: (2021-12-01) -
Factors modifying the course of spinal muscular atrophy 5q
by: M. A. Akhkiamova, et al.
Published: (2024-01-01)